[Skip to content]

Enter search here...
Worcestershire Treatment Pathways
.
.

Secukinumab for treating moderate to severe plaque psoriasis (NICE TA350) (DRAFT)

This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and /or carer.  Health care professionals must be prepared to justify any deviation from this guidance.

Pathway Information

Secukinumab for treating moderate to severe plaque psoriasis (NICE TA350)

Page last updated: 15 December 2015